Actively Recruiting
Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
Led by Peking University People's Hospital · Updated on 2026-04-02
80
Participants Needed
1
Research Sites
71 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Lung malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. CDH3 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous epithelial cells. A new PET probe, 68Ga-TOI-1, targeting CDH3 has been developed with better affinity and selectivity than previous probes. Preclinical data support its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of lung tumors, providing a new and precise evaluation method for lung malignant tumors.
CONDITIONS
Official Title
Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, male or female, with an ECOG performance status of 0 or 1
- Availability of complete clinical and imaging data
- Life expectancy of at least 12 weeks
- Hematology and liver and kidney function within specified normal limits
- No prior radiotherapy or chemotherapy; eligible for surgical resection or biopsy for pathological diagnosis or highly suspected malignant pulmonary nodules
- Pathologically confirmed lung cancer by biopsy before neoadjuvant therapy; life expectancy at least 12 weeks
- Ability to provide adequate tumor tissue for testing and research
You will not qualify if you...
- Women who are pregnant, planning pregnancy, or breastfeeding
- History of other malignant tumors or prior anti-tumor therapies
- Poor or missing PET scan image quality not meeting analysis standards
- Presence of claustrophobia or other mental illnesses
- Any conditions considered inappropriate for participation by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
Research Team
K
Kezhong Chen, MD
CONTACT
Y
Yutao Li, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here